Celldex Therapeutics, Inc. has initiated their Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE) with the dosing of the first patient. EoE is a chronic inflammatory disease that affects the esophagus and is the most common form of eosinophilic gastrointestinal disease. The objective of this study is to assess the effectiveness and safety of subcutaneous barzolvolimab in patients with active EoE.
The study will be conducted at approximately 60 clinical trial centers across 8 countries, including the United States. The primary endpoint of the study is to reduce mast cell infiltration within the esophageal tissue, while secondary endpoints include alleviating symptoms related to difficulty swallowing (dysphagia), reducing eosinophil infiltration within the esophageal tissue, and ensuring safety.
EoE is characterized by an excessive presence of eosinophils in the esophagus, leading to symptoms such as difficulty swallowing, chest pain, vomiting, and food blockage.